Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2019.07.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of fibroblast growth factor 2 on neovascular vessels depends on the stage of angiogenesis.
Heliyon
November 2024
Department of Ophthalmology, Kansai Medical University, Osaka, Japan.
Objective: The exact relationship between fibroblast growth factor 2 (FGF2) and choroidal neovascularization (CNV) remains unclear. In this study, using optical coherence tomography angiography (OCTA) and FGF2-tg mice which are transgenic mice with a rhodopsin promoter/FGF2 gene fusion, we aimed to investigate the dynamics of FGF2's role in angiogenesis over time.
Methods: We developed laser-induced CNV models of FGF2-tg and wild-type (WT) mice and then separated them into two groups using different laser photocoagulation (PC) conditions.
Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration.
Mol Ther
November 2023
Chengdu Origen Biotechnology Co., Ltd, Chengdu, China; Chengdu Kanghong Pharmaceuticals Group Co Ltd, Chengdu, China; Therapeutic Proteins Key Laboratory of Sichuan Province, Chengdu, China. Electronic address:
The upregulation of vascular endothelial growth factor (VEGF) is strongly associated with the development of choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (nAMD). Currently, the standard treatment for nAMD involves frequent intravitreal injections of anti-VEGF agents, which inhibit the growth of new blood vessels and prevent leakage. However, this treatment regimen places a significant burden on patients, their families, and healthcare providers due to the need for repeated visits to the clinic for injections.
View Article and Find Full Text PDFA hypothetical therapeutic effect of light peripheral panretinal photocoagulation in neovascular age-related macular degeneration.
Med Hypothesis Discov Innov Ophthalmol
December 2022
Department of Retina and Uvea, ASG Eye Hospital, Kolkata, West Bengal, India.
Background: Vascular endothelial growth factor (VEGF) is a significant modulator of ocular angiogenesis, including that of neovascular age-related macular degeneration (nAMD). Intravitreal injection of anti-VEGF is the benchmark treatment for most retinal vascular diseases, including nAMD, diabetic maculopathy, and macular edema secondary to retinal venous occlusion. Anti-VEGF treatment is a high-frequency, time-consuming, non-cost-effective therapy, especially in countries and regions with limited resources.
View Article and Find Full Text PDFPreclinical evaluation of ADVM-062, a novel intravitreal gene therapy vector for the treatment of blue cone monochromacy.
Mol Ther
July 2023
Adverum Biotechnologies, Inc., Redwood City, CA 94063, USA. Electronic address:
Blue cone monochromacy (BCM) is a rare X-linked retinal disease characterized by the absence of L- and M-opsin in cone photoreceptors, considered a potential gene therapy candidate. However, most experimental ocular gene therapies utilize subretinal vector injection which would pose a risk to the fragile central retinal structure of BCM patients. Here we describe the use of ADVM-062, a vector optimized for cone-specific expression of human L-opsin and administered using a single intravitreal (IVT) injection.
View Article and Find Full Text PDFThe effect of a brief, unplanned treatment delay on neovascular age-related macular degeneration patients: a retrospective cohort study.
Sci Rep
February 2023
Department of Ophthalmology, University of North Carolina (UNC), 2226 Nelson Hwy Suite 220, Chapel Hill, NC, 27517, USA.
Non-compliance to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy can result in increased disease activity in neovascular age-related macular degeneration (nAMD). Our study aims to determine effects of unplanned delay in anti-VEGF injection treatment for nAMD. This retrospective observational study included patients with delays in receiving intravitreal injections for nAMD treatment from March to May 2020 by at least 21 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!